HC Wainwright Reiterates Neutral Rating for HilleVax (NASDAQ:HLVX)

HilleVax (NASDAQ:HLVX)‘s stock had its “neutral” rating reiterated by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $2.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 25.79% from the company’s previous close.

HilleVax Trading Down 1.2 %

HilleVax stock opened at $1.59 on Monday. HilleVax has a 12-month low of $1.55 and a 12-month high of $16.66. The firm has a 50-day moving average price of $1.82 and a 200-day moving average price of $1.86. The firm has a market capitalization of $79.19 million, a PE ratio of -0.51 and a beta of 0.76.

HilleVax (NASDAQ:HLVX) last released its earnings results on Friday, March 28th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.02). As a group, sell-side analysts predict that HilleVax will post -2.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in HLVX. Intech Investment Management LLC bought a new stake in HilleVax during the 4th quarter valued at about $26,000. SG Americas Securities LLC increased its position in shares of HilleVax by 61.6% during the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock worth $38,000 after acquiring an additional 6,916 shares during the period. Ieq Capital LLC boosted its holdings in shares of HilleVax by 71.1% in the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock valued at $47,000 after purchasing an additional 9,344 shares during the period. Barclays PLC lifted its holdings in shares of HilleVax by 255.6% in the 3rd quarter. Barclays PLC now owns 42,033 shares of the company’s stock worth $74,000 after buying an additional 30,213 shares during the period. Finally, Bank of Montreal Can grew its position in shares of HilleVax by 47.1% during the 4th quarter. Bank of Montreal Can now owns 35,763 shares of the company’s stock worth $74,000 after buying an additional 11,459 shares in the last quarter. 86.42% of the stock is currently owned by institutional investors.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.